X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the partnership, EVERSANA will support the expansion of its portfolio of pain and endocrinology products in the U.S., including Flector (diclofenac epolamine), a topical prescription therapy for acute pain due to minor strains, sprains, and contusions.
Lead Product(s): Diclofenac Epolamine
Therapeutic Area: Neurology Product Name: Flector
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Yaral Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 22, 2023
Details:
Nelarabine Injection is a nucleoside metabolic inhibitor indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma in adult and pediatric patients age 1 year and older.
Lead Product(s): Nelarabine
Therapeutic Area: Oncology Product Name: Nelarabine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Shorla Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
Under the agreement, EVERSANA will support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc (dasatinib) for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL).
Lead Product(s): Dasatinib
Therapeutic Area: Oncology Product Name: Dasynoc
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Xspray Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 24, 2023
Details:
CAMCEVI is the first-ever ready-to-inject sterile formulation of leuprolide for subcutaneous injection that comes in a pre-filled syringe with no mixing required. In an open-label, single-arm study of 137 adults who received 42mg of CAMCEVI on Day 0 and Week 24.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Camcevi
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Accord BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 29, 2022
Details:
Under the partnership OWP will launch and commercialize its oral liquid formulations for neuroscience disorders. OWP has also received IND for Lamotrigine in multiple therapies for epilepsy, schizophrenia, bipolar disorder, major depressive, anxiety disorder, and migraines.
Lead Product(s): Lamotrigine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: OWP Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 05, 2022
Details:
The partnership aims at making lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration (FDA) and subsequent BLA.
Lead Product(s): Lenzilumab
Therapeutic Area: Immunology Product Name: Humaneered
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Humanigen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 10, 2021
Details:
Gimoti™ is a nasal spray launched for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Product launch provides healthcare providers a novel treatment approach for patients suffering from symptoms of acute and recurrent diabetic gastroparesis.
Lead Product(s): Metoclopramide
Therapeutic Area: Gastroenterology Product Name: Gimoti
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Evoke Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Mirum will utilize EVERSANA’s commercialization platform to provide integrated nationwide distribution, specialty pharmacy, patient services and Hub support for maralixibat, if approved.
Lead Product(s): Maralixibat
Therapeutic Area: Genetic Disease Product Name: LUM001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mirum Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 15, 2020
Details:
Zosano and EVERSANA will utilize EVERSANA’s commercial execution expertise for marketing, market access, distribution, sales force deployment, reimbursement, and patient adherence support services. EVERSANA to commercialize and distribute Qtrypta™ in the United States.
Lead Product(s): Zolmitriptan
Therapeutic Area: Neurology Product Name: Qtrypta
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zosano Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
